NUT family member 2H, pseudogeneGenealiases: FAM22HP · NUTMHP
Q-omics provides the consensus-scored NUTM2HP profile across patient tissues and cancer cell-line models. NUTM2HP expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NUTM2HP is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, NUTM2HP RNA expression shows 14,261 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LUSC, and THYM as cancer lineages where NUTM2HP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTM2HP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTM2HP survival associations across molecular data types. NUTM2HP RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTM2HP RNA expression–survival associations across cancer types. High NUTM2HP expression shows unfavorable associations in ACC and UVM, but favorable associations in BLCA, LGG, SKCM and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for NUTM2HP RNA expression.
This table summarizes NUTM2HP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NUTM2HP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTM2HP shows lower tumor expression in LUSC, BRCA, KICH, LUAD and BLCA and higher tumor expression in LIHC. The LUSC box plot shows higher NUTM2HP RNA expression in normal versus tumor tissue (log2 FC = −0.158, t-test p < 0.001).
This table shows molecular features associated with NUTM2HP in patient tissues and cancer cell lines. In patient samples, NUTM2HP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
